daniele santini
daniele santini
professor in general pathology
Email verificata su unicampus.it
Titolo
Citata da
Citata da
Anno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
20002010
A controlled-release microchip
JT Santini, MJ Cima, R Langer
Nature 397 (6717), 335-338, 1999
9991999
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
5702009
Management of cancer pain: ESMO clinical practice guidelines
CI Ripamonti, D Santini, E Maranzano, M Berti, F Roila, ...
Annals of oncology 23 (suppl_7), vii139-vii154, 2012
4872012
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
4702009
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
3722003
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
3442007
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3202002
Tissue invasion and metastasis: Molecular, biological and clinical perspectives
WG Jiang, AJ Sanders, M Katoh, H Ungefroren, F Gieseler, M Prince, ...
Seminars in cancer biology 35, S244-S275, 2015
2722015
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
2682008
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises
F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ...
Cancer treatment reviews 41 (2), 114-121, 2015
2272015
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2002003
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
1962008
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
1922007
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
1792006
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85, 2010
1782010
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ...
Journal of interferon & cytokine research 25 (3), 144-151, 2005
1702005
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ...
PloS one 6 (4), 2011
1652011
Designing a broad-spectrum integrative approach for cancer prevention and treatment
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35, S276-S304, 2015
1592015
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia, D Santini, M Marra, B Vincenzi, G Tonini, A Budillon
Endocrine-related cancer 13 (1), 7-26, 2006
1482006
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20